New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
Executive Summary
The addressable patient population in the US could increase by 4.5 million if new trial is successful.
You may also be interested in...
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval
John Thero insists company is focused on approval and launch, as interest in European rights grow.
Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.